See How Mylan Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Mylan Inc ( MYL) is the #16 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period. In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the list of stocks with strong buyback activity was ranked according to those averages.

Investors are often keenly interested in knowing which companies are buying back their own stock, because companies often will only make such a move if they feel their stock is undervalued. Mylan Inc is a company with strong buyback activity that is also considered a compelling buy by analysts; a bullish investor could take this to mean that sharp analyst minds came to the same bullish conclusion as the company itself that the stock is a good value, and therefore the stock should do well in the future.

START SLIDESHOW:
Top 25 Analyst Picks With Strong Stock Repurchase Activity »

Analysts studying companies buying back their own stock will also factor into their analysis that future earnings will now be spread over a smaller share count, thereby increasing the per-share earnings the remaining shares will enjoy, versus what that same number would have been absent the stock buyback activity.

According to the ETF Finder at ETF Channel, MYL makes up 3.77% of the iShares Nasdaq Biotechnology ETF (IBB) which is trading lower by about 1% on the day Tuesday.

MYL operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson (JNJ) which is up about 0.1% today, and Novartis (NVS) trading higher by about 0.5%. Below is a three month price history chart comparing the stock performance of MYL, versus JNJ and NVS.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids